The U.S. Food and Drug Administration has issued an approval (status AP) for ANDA076877, an abbreviated new drug application submitted by Senores Pharms. The application covers two oral tablet products containing gabapentin at strengths of 600 mg and 800 mg.
Both products are currently marked as discontinued in the FDA database. The original submission (submission number 1) received approval on July 6, 2006, and a labeling supplement (submission number 4) was approved on September 24, 2014.
Actualités réglementaires24 août 2026•1 min de lecture
FDA Approves ANDA076877 for Gabapentin Tablets (Discontinued)
FDA approved ANDA076877 for gabapentin 600mg and 800mg oral tablets submitted by Senores Pharms; both products are listed as discontinued.
Compilé par l'équipe PharmaCountry · Source : FDA.gov
Évaluations
(0)
(0)
(0)
(0)
(0)
Plus d'articles
Voir tous les articlesRecherches & Rapports
Global Finished Dosage Manufacturing Landscape 2026
5 oct. 2026
Actualités réglementairesKorea Korus hit with 1‑month manufacturing suspension over missing post‑marketing safety test
28 sept. 2026
AnalysePharma distributors set delivery cut‑offs ahead of Chuseok holiday (Sep 21‑23)
28 sept. 2026
Laissez votre note